Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Cancer- and cancer treatment-related conditions
Stage/Subtype:  fatigue
Country:  U.S.A.
Trial Type:  Treatment
Results 1-10 of 10 for your search:
Start Over
Standard of Care Therapy with or without Stereotactic Radiosurgery and/or Surgery in Treating Patients with Limited Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR002, NCI-2014-01810, NCT02364557
PEG-Interferon Alfa-2a or Hydroxyurea in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MPD-RC 112, NCI-2012-00269, NCT01259856
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients with Brain Metastases That Have Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N107C, NCI-2011-02676, CDR0000701474, NCCTG-N107C, NCT01372774
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 112121, NCI-2014-02104, NCT02158936
A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 60 and over
Trial IDs: E1411, NCI-2011-02980, CDR0000707057, ECOG-E1411, NCT01415752
Lower or Standard Dose Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU021407I, NCI-2015-00011, Mod14-008756-03, NCT02368886
Neurocognitive Function in Patients With Newly Diagnosed Brain Metastases Undergoing Stereotactic Radiosurgery
Phase: No phase specified
Type: Health services research, Supportive care, Treatment
Age: 18 and over
Trial IDs: 12105, NCI-2013-01358, NAGKC 12-02, NCT01821443
Iobenguane I 131 in Treating Patients With Refractory Neuroblastoma or Metastatic Pheochromocytoma
Phase: No phase specified
Type: Supportive care, Treatment
Age: 1 and over
Trial IDs: 2012LS107, NCI-2013-01933, NCT01850888
Start Over